WO1999020742A3 - A packaging cell line producing siv-pseudotyped mlv - Google Patents

A packaging cell line producing siv-pseudotyped mlv Download PDF

Info

Publication number
WO1999020742A3
WO1999020742A3 PCT/EP1998/006610 EP9806610W WO9920742A3 WO 1999020742 A3 WO1999020742 A3 WO 1999020742A3 EP 9806610 W EP9806610 W EP 9806610W WO 9920742 A3 WO9920742 A3 WO 9920742A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell line
packaging cell
line producing
mlv
siv
Prior art date
Application number
PCT/EP1998/006610
Other languages
French (fr)
Other versions
WO1999020742A2 (en
Inventor
Stefano Indraccolo
Fabrizio Mammano
Original Assignee
Univ Padova
Stefano Indraccolo
Fabrizio Mammano
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Padova, Stefano Indraccolo, Fabrizio Mammano filed Critical Univ Padova
Priority to EP98956852A priority Critical patent/EP1025208A2/en
Priority to AU13349/99A priority patent/AU1334999A/en
Publication of WO1999020742A2 publication Critical patent/WO1999020742A2/en
Publication of WO1999020742A3 publication Critical patent/WO1999020742A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a packaging cell line packaging an MLV-based recombinant retroviral genome into a particle comprising an SIV envelope, and a pseudotyped retroviral particle produced by the packaging cell line. Both, the packaging cell line and the retroviral particle, when comprising therapeutic genes, are especially useful for somatic gene therapy, preferably in mammals including humans.
PCT/EP1998/006610 1997-10-20 1998-10-19 A packaging cell line producing siv-pseudotyped mlv WO1999020742A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP98956852A EP1025208A2 (en) 1997-10-20 1998-10-19 A packaging cell line producing siv-pseudotyped mlv
AU13349/99A AU1334999A (en) 1997-10-20 1998-10-19 A packaging cell line producing siv-pseudotyped mlv

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK1196/97 1997-10-20
DK119697 1997-10-20

Publications (2)

Publication Number Publication Date
WO1999020742A2 WO1999020742A2 (en) 1999-04-29
WO1999020742A3 true WO1999020742A3 (en) 1999-07-01

Family

ID=8102058

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/006610 WO1999020742A2 (en) 1997-10-20 1998-10-19 A packaging cell line producing siv-pseudotyped mlv

Country Status (3)

Country Link
EP (1) EP1025208A2 (en)
AU (1) AU1334999A (en)
WO (1) WO1999020742A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0817858T3 (en) 1995-03-09 2003-08-11 Gsf Forschungszentrum Umwelt Vectors containing therapeutic genes for antimicrobial peptides for use in gene therapy
EP1115290B1 (en) 1998-10-01 2009-03-04 University of Southern California Retroviral gene delivery system and methods of use
CA2425293A1 (en) * 2000-10-10 2002-04-18 Institut Fur Virologie Teilrechtsfahiges Institut An Der Veterinarmedizi Nischen Universitat Wien A novel system for the evaluation of the activity and/or specificity of a viral component
WO2008151633A2 (en) * 2007-06-15 2008-12-18 Skau Aps Vectors for vaccines against lentivirus infections
NZ592070A (en) 2008-09-26 2012-07-27 Tocagen Inc Gene therapy vectors and humanized yeast cytosine deaminase triple mutant
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
EP2632491A4 (en) 2010-10-31 2014-10-01 Tocagen Inc Enhanced cancer treatment and monitoring using recombinant vectors
ES2786051T3 (en) 2012-10-25 2020-10-08 Tocagen Inc Retroviral vector with mini-promoter cassette
US9642921B2 (en) 2012-12-20 2017-05-09 Tocagen Inc. Cancer combination therapy and recombinant vectors
US11279949B2 (en) 2015-09-04 2022-03-22 Denovo Biopharma Llc Recombinant vectors comprising 2A peptide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011524A1 (en) * 1992-11-09 1994-05-26 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Targetable vector particles
WO1997017457A2 (en) * 1995-11-08 1997-05-15 Whitehead Institute For Biomedical Research Stable packaging cell line producing pseudotyped retroviruses
WO1998038325A2 (en) * 1997-02-27 1998-09-03 Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts Retroviral vectors, method for the production and the use thereof for gene transfer in cd4-positive cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011524A1 (en) * 1992-11-09 1994-05-26 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Targetable vector particles
WO1997017457A2 (en) * 1995-11-08 1997-05-15 Whitehead Institute For Biomedical Research Stable packaging cell line producing pseudotyped retroviruses
WO1998038325A2 (en) * 1997-02-27 1998-09-03 Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts Retroviral vectors, method for the production and the use thereof for gene transfer in cd4-positive cells

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
C.P. SPIES ET AL.,: "Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein alters the conformation of the external domain", JOURNAL OF VIROLOGY, vol. 68, no. 2, 1994, pages 585 - 591, XP002101256 *
C.YANG AND R. COMPANS: "Analysis of the cell fusion activities of chimeric simian immunodeficiency virus-murine leukemia virus envelope proteins: Inhibitory effects of the virus-murine leukemia virus envelope proteins: Inhibitory effects of the R peptide", JOURNAL OF VIROLOGY, vol. 70, no. 1, 1996, pages 248 - 254, XP002101006 *
K. ZINGLER AND D.R. LITTMAN: "Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein increases Env incorporation into particles and fusogenicity and infectivity", JOURNAL OF VIROLOGY, vol. 67, no. 5, 1993, pages 2824 - 2831, XP002101007 *
MAMMANO F M ET AL: "TRUNCATION OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 ENVELOPE GLYCOPROTEIN ALLOWS EFFICIENT PSEUDOTYPING OF MOLONEY MURINE LEUKEMIA VIRUS PARTICLES AND GENE TRANSFER INTO CD4+ CELLS", JOURNAL OF VIROLOGY, vol. 71, no. 4, April 1997 (1997-04-01), pages 3341 - 3345, XP002074198 *
S. INDRACCOLO ET AL.,: "Pseudotyping of Moloney leukemia virus-based retroviral vectors with simian immunodeficiency virus envelope leads to targeted infection of human CD4+ lymphoid cells", GENE THERAPY, vol. 5, no. 2, February 1998 (1998-02-01), pages 209 - 217, XP002101010 *
S. INDRACCOLO ET AL.: "DNA immunization of mice aginst SIVmac293 gag and env using rev-independent expression plasmids", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 14, no. 1, January 1998 (1998-01-01), pages 83 - 90, XP002101009 *
SCHNIERLE B S ET AL: "PSEUDOTYPING OF MURINE LEUKEMIA VIRUS WITH THE ENVELOPE GLYCOPROTEINS OF HIV GENERATES A RETROVIRAL VECTOR WITH SPECIFICITY OF INFECTION FOR CD4-EXPRESSING CELLS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 94, August 1997 (1997-08-01), pages 8640 - 8645, XP002074100 *
WILK T ET AL: "RETAINED IN VITRO INFECTIVITY AND CYTOPATHOGENICITY OF HIV-1 DESPITE TRUNCATION OF THE C-TERMINAL TAIL OF THE ENV GENE PRODUCT", VIROLOGY, vol. 189, 1992, pages 167 - 177, XP002074097 *

Also Published As

Publication number Publication date
EP1025208A2 (en) 2000-08-09
AU1334999A (en) 1999-05-10
WO1999020742A2 (en) 1999-04-29

Similar Documents

Publication Publication Date Title
CA2092195A1 (en) Retroviral packaging cell line
AU5788096A (en) Plasmid for delivery of nucleic acids to cells and methods of use
WO1999020742A3 (en) A packaging cell line producing siv-pseudotyped mlv
CA2223691A1 (en) Tumor- or cell-specific herpes simplex virus replication
PL332876A1 (en) Lentoviral vectors
CA2182303A1 (en) Method of preparing a viral vector by homologous intermolecular recombination
MX9800145A (en) Tissue specific viral vectors.
EP0979101A4 (en) Recombinant canine adenovirus (cav) containing exogenous dna
WO2003082200A3 (en) Potent oncolytic herpes simplex virus for cancer therapy
CA2328404A1 (en) Novel lentiviral packaging cells
WO1996003515A3 (en) Surface expression of enzyme in gene directed prodrug therapy
WO1997005255A3 (en) Helper viruses for preparing recombinant viral vectors
AU4723596A (en) Method for preparing a recombinant adenovirus genome
KR960001819B1 (en) Viral vector coding for a glycoprotein of the virus responsible
EP1484409A3 (en) Expression vector comprising short-lived drug resistance gene
AU6415496A (en) Encapsulated cells producing viral particles
WO2005038035A3 (en) Methods for producing and using in vivo pseudotyped retroviruses
CA2278808A1 (en) Methods for cultivating cells and propagating viruses
EP1070122A4 (en) Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery
CA2329510A1 (en) Promoter sequence which is expressed in anthers and in pollen
CA2282394A1 (en) Retroviral vectors, methods for their preparation and their use for gene transfer into cd4-positive cells
WO2000071078A3 (en) Composition designed for implementing an antitumoral or antiviral treatment in a mammal
MX9707910A (en) Glucose-inducible recombinant viral vector.
ATE226638T1 (en) RETROVIRAL VECTOR AND ITS USE IN GENE THERAPY
AU7514087A (en) Vaccine containing the protein f of the aids virus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1998956852

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1998956852

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1998956852

Country of ref document: EP